$420M fund comes to LYFE, with plans for a trans-Pa­cif­ic in­vest­ment strat­e­gy in­tro­duc­ing US biotechs to Chi­na

Less than two years af­ter its launch, Shang­hai-based LYFE Cap­i­tal has come up with an up­sized biotech ven­ture fund. And this time it’s spread­ing its wings di­rect­ly in­to the US mar­ket, where it plans to start mak­ing some new bets on a slate of life sci­ence ven­tures in­ter­est­ed in de­vel­op­ing a Chi­na strat­e­gy.

LYFE II came up with $288 mil­lion and RMB 900 mil­lion, or $131 mil­lion, for a to­tal of about $420 mil­lion. In late 2015 LYFE de­buted with $298 mil­lion in its first fund, rac­ing through that at a fast pace. This new fund al­so in­cludes a new of­fice in Pa­lo Al­to, CA, where the ven­ture group plans to add more stakes in the phar­ma­ceu­ti­cal, med­ical de­vice, di­ag­nos­tics, an­i­mal health, health­care ser­vices and dig­i­tal health sec­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.